Reply to ‘The role of tranexamic acid in trauma — a life-saving drug with proven benefit’

Competing interests

E.E.M. currently receives research support from Haemonetics, Instrumentation Laboratory, Stago, Hemosonics, Diapharma, Prytime, Humacyte and Genentech; he is a co-founder of ThromboTherapeutics; he is listed as inventor on the following patents relating to blood coagulation or fibrinolysis (including assays): WO-2016073668-A1 (assignee: The Regents Of The University Of Colorado; status: published); US-9354243-B2 (assignee: Haemonetics Corporation, The Regents Of The University Of Colorado, A Body Corporate; status: granted); WO-2019014595-A1 (assignee: Thrombo Therapeutics, Inc.; status: published); EP-3215634-A1 (assignee: The Regents of the University of Colorado; status: published); EP-3303943-A1 (assignee: The Regents of The University of Colorado, A Body Corporate; status: published); WO-2021158799-A1 (assignee: The Regents Of The University Of Colorado, A Body Corporate; status: published); and US-2020208194-A1 (assignee: Massachusetts Institute Of Technology, University Of Colorado; status: published). H.B.M. receives research support from Haemonetics and Instrumentation Laboratory; he is a co-founder of ThromboTherapeutics; he is listed as inventor on the following patents relating to blood coagulation or fibrinolysis (including assays): WO-2016073668-A1 (assignee: The Regents Of The University Of Colorado; status: published); WO-2019014595-A1 (assignee: Thrombo Therapeutics, Inc.; status: published); EP-3215634-A1 (assignee: The Regents of the University of Colorado; status: published); and US-2020208194-A1 (assignee: Massachusetts Institute Of Technology, University Of Colorado; status: published). A.S. declares no competing interests.

留言 (0)

沒有登入
gif